The study reviewed US medical claims databases from 2005 to 2021 and compared CVD outcomes in narcolepsy patients and ...

The link between narcolepsy and cardiovascular disease (CVD) was strengthened by new evidence that the relationship applied ...

From baseline, patients treated with AXS-12 had an 83% reduction in cataplexy attacks at the end of 5 weeks compared with a ...

AXS-12, known as reboxetine back when it was available as an antidepressant in the United States, may decrease cataplexy ...

For the next in our series of conditions GPs might rarely encounter, Neurology consultant Dr Clare Bolton provides an ...

Jazz Pharmaceuticals said on Tuesday that it had agreed to a settlement of $145 million to resolve a series of antitrust lawsuits related to its narcolepsy drug, Xyrem.

Among patients with narcolepsy, AXS-12 (reboxetine) vs placebo significantly reduced the frequency of cataplexy attacks.

Narcolepsy is a nervous system disorder that involves your brain. You struggle to manage sleep patterns and stay awake. No matter how much rest you got the night before, an intense urge to sleep ...

USA: A retrospective cohort study using Medicare and commercial insurance data has found that narcolepsy is associated with ...

The paper, titled “Characterization and Treatment Patterns of Patients Treated With Immediate-Release Sodium Oxybate for Narcolepsy: A Propensity-Matched Cohort Study,” was published online in ...

Retrospective analysis reveals no significant differences in comorbidities in narcolepsy patients treated vs. not treated with sodium oxybate ...